ARTICLE | Company News
Rapidscan Pharma Solutions Inc., General Electric sales and marketing update
May 23, 2011 7:00 AM UTC
Rapidscan granted General Electric exclusive co-commercialization rights to Rapiscan regadenoson in the U.K. and Germany. The A2A adenosine receptor ( ADORA2A) agonist is approved in the EU as a phar...